This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Market Need
By 2025 the global therapeutic peptide market is expected to reach sales of >$49 billion. As the market grows and the use of therapeutic peptides increases there remains significant challenges with peptide delivery such as:
- Poor solubility
- Gel formation
- Formation of fibrils or particles
- Hydrolytic cleavage
- Formation of charge variants
- The Arestat™ technology overcomes these challenges and enables superior format of therapeutic peptide products
What Arecor can do
Arecor has an excellent track record developing difficult-to-achieve product profiles. Our Arestat™ technology offers a series of formulation options that have been specifically designed to overcome challenges associated with delivering stable aqueous formulations of therapeutic peptides.
Arecor is leveraging its unique formulation platform to develop a portfolio of proprietary products enabling improved treatments for diabetes – see our products.